We have begun analyzing our preliminary 2023 Integrated Delivery Network (IDN) survey data and have found that oncology pharmacists are once again looking forward to meeting manufacturer team members in person. Our 2022 research found providers still grappling with COVID-19 impacts and preferring virtual meetings. Now, with a better understanding of COVID and its effects, providers’ preferences are shifting toward in-person interactions, although virtual options remain in the mix.
Source: HMP Market Access Insights.
Abbreviations: HCP, health care professional.
We are now conducting our follow-up interviews, and beyond the survey findings the oncology pharmacists tell us:
Stay tuned for more insights and the publication of our 2023 IDN Oncology Trend Survey next month. Until then, please reach out with any comments or questions you may have.
Navigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.
Emma BijesseWelcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.
Taylor CrutisonWelcome to the February 2024 edition of our Monthly Insight Series, featuring key findings from our recent column in the Journal of Clinical Pathways. The column was the first in a series on oncologists' awareness and use of pathways.
Lee Blansett